Additionally, in a phase I/II study in Japan, SART1-pulsed Dex enhanced cytotoxic T-cell responses in patients with advanced squamous cell carcinoma of the esophagus [89]. The gene discussed is SART1; the disease is esophageal squamous cell carcinoma.